1. Inicio
  2. Proyectos y Estudios
  3. RECOLECCIÓN DE MUESTRAS DE TEJIDO SIN INTERVENCIÓN, RETROSPECTIVA, DE SEGUIMIENTO AL ESTUDIO 20050244 DE AMGEN (ESTUDIO DE DENOSUMAB EN COMPARACIÓN CON ÁCIDO ZOLEDRÓNICO EN EL TRATAMIENTO DE METÁSTASIS ÓSEAS, EN SUJETOS CON CÁNCER AVANZADO O MIELOMA MÚLTI PLE).

RECOLECCIÓN DE MUESTRAS DE TEJIDO SIN INTERVENCIÓN, RETROSPECTIVA, DE SEGUIMIENTO AL ESTUDIO 20050244 DE AMGEN (ESTUDIO DE DENOSUMAB EN COMPARACIÓN CON ÁCIDO ZOLEDRÓNICO EN EL TRATAMIENTO DE METÁSTASIS ÓSEAS, EN SUJETOS CON CÁNCER AVANZADO O MIELOMA MÚLTI PLE).

Datos básicos

Código:
ADX13036
Protocolo:
ADX13036
EUDRACT:
NCT:
Centro:
Dotación:
Año de incio:
Año de finalización:
2015
PI BIOMÉDICA

Documentos

  • No hay documentos

Participantes

Grupos

Resultados del Ensayo Clínico

18F-FDG-PET/CT response after first-line treatment as a prognostic factor for survival in peripheral T-cell lymphoma: a Spanish retrospective study.

Cordoba, Raul; (...); Martin Garcia-Sancho, Alejandro

Article. 10.1080/17474086.2024.2313457. 2024


90 yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: Updated results after a median follow-up of 8.5 years from the GOTEL trial.

Provencio-Pulla, Mariano; (...); Rueda, Antonio

Meeting Abstract. 10.1200/JCO.2018.36.15_suppl.7550. 2018


A Descriptive Study of 103 Primary Cutaneous B-Cell Lymphomas: Clinical and Pathological Characteristics and Treatment from the Spanish Lymphoma Oncology Group (GOTEL).

Martínez-Banaclocha N; (...); Gumà J

Article. 10.3390/cancers16051034. 2024


A phase Ib study of CC-90011, a potent, reversible, oral LSD1 inhibitor, plus etoposide and cisplatin (EP) or carboplatin (EC) in patients (Pts) with first-line (1L) extensive-stage (ES) small cell lung cancer (SCLC): Updated results

Ponce Aix, S.; (...); Paz-Ares, L.

Meeting Abstract. 2021


A Randomized, Open-Label Phase II Study Evaluating Emibetuzumab Plus Erlotinib and Emibetuzumab Monotherapy in MET Immunohistochemistry Positive NSCLC Patients with Acquired Resistance to Erlotinib.

Camidge DR; (...); Smit E

Article. 10.1016/j.cllc.2022.03.003. 2022


Adjuvant chemoradiation in gastric cancer: long-term outcomes and prognostic factors from a single institution

Bruixola, G; (...); Aparicio, J

Article. 10.5301/tj.5000344. 2015


Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.

Passaro, A; (...); Cho, B C

Article. 10.1016/j.annonc.2023.10.117. 2024


An internally validated new clinical and inflammation-based prognostic score for patients with advanced hepatocellular carcinoma treated with sorafenib

Diaz-Beveridge, R; (...); Aparicio, J

Article. 10.1007/s12094-017-1720-4. 2018


An open-label, multicenter, phase 2 study of the safety and efficacy of navtemadlin (KRT-232) in patients with TP53 wild-type relapsed/refractory small cell lung cancer.

Dowlati, Afshin; (...); Carpeno, Javier de Castro

Meeting Abstract. 2022


Analysis of autophagy gene polymorphisms in Spanish patients with head and neck squamous cell carcinoma

Fernandez-Mateos, J; (...); Gonzalez-Sarmiento, R

Article. 10.1038/s41598-017-07270-0. 2017


Are there differences by sex in lung cancer characteristics at diagnosis? -a nationwide study.

Ruano-Ravina A; (...); Oramas J

Article. 10.21037/tlcr-21-559. 2021


Assessment of the Feasibility and Safety of Durvalumab for Treatment of Solid Tumors in Patients With HIV-1 Infection The Phase 2 DURVAST Study

Gonzalez-Cao, M; (...); Rosell, R

Article. 10.1001/jamaoncol.2020.0465. 2020


Avelumab in Combination With Cetuximab and Chemotherapy as First-Line Treatment for Patients With Advanced Squamous NSCLC.

Andric, Zoran; (...); Ciardiello, Fortunato

Article. 10.1016/j.jtocrr.2022.100461. 2023


Baseline circulating myeloid-derived suppressor cells correlate with neutrophil-to-lymphocyte ratio and overall survival in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors

Garcia-Sanchez, J.; (...); Lahoz, A.

Meeting Abstract. 2021


Bulky mass tumor in right foot

Coloma, CS; (...); Gomez, OMN

Editorial Material. 10.1093/jjco/hyv075. 2015


Capmatinib vs docetaxel as second- or third-line (2/3L) therapy in patients (pts) with METex14-mutated advanced NSCLC (aNSCLC): The GeoMETry-III trial

Vidal, O. J. Juan; (...); Wolf, J.

Meeting Abstract. 10.1016/j.annonc.2023.09.2424. 2023


CD8+ NKs as a potential biomarker of complete response and survival with lenalidomide plus R-GDP in the R2-GDP-GOTEL trial in recurrent/refractory diffuse large B cell lymphoma.

Hontecillas-Prieto L; (...); de la Cruz-Merino L

Article. 10.3389/fimmu.2024.1293931. 2024


Circulating myeloid-derived suppressor cells and regulatory T cells as immunological biomarkers in refractory/relapsed diffuse large B-cell lymphoma: translational results from the R2-GDP-GOTEL trial

Jimenez-Cortegana, C; (...); de la Cruz-Merino, L

Article. 10.1136/jitc-2020-002323. 2021


Clinical and pathological characteristics of peripheral T-cell lymphomas in a Spanish population: a retrospective study.

Rodriguez-Pinilla SM; (...); Cordoba, Raul

Article. 10.1111/bjh.16741. 2021


Clinical characteristics and survival in stage I-IIIA lung cancer resected patients in Spain, analyzed in the Thoracic Tumors Registry (TTR)

Franco, FF; (...); Provencio, M

Meeting Abstract. 10.1016/j.annonc.2021.08.1771. 2021


Comprehensive cross-platform comparison of methods for non-invasive EGFR mutation testing: Results of the RING observational trial.

Romero A; (...); Provencio M

Article. 10.1002/1878-0261.12832. 2020


Consolidation treatment with yttrium-90 ibritumomab tiuxetan after new induction regimen in advanced stage follicular lymphoma: update results from the Spanish Lymphoma Oncology Group trial after a median follow-up of 8.5-years

Provencio, M; (...); Rueda, A

Letter. 10.1080/10428194.2018.1509322. 2019


Correction to: SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022).

García-Campelo R; (...); Dómine M

Correction. 10.1007/s12094-023-03290-7. 2023


Correction: Pardo-Sánchez et al. Increased Tumor Growth Rate and Mesenchymal Properties of NSCLC-Patient-Derived Xenograft Models during Serial Transplantation. Cancers 2021, 13 , 2980.

Pardo-Sanchez, Jose Miguel; (...); Farràs R

Article. 10.3390/cancers13194825. 2021


Corrigendum to 'First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update': [ESMO Open Volume 6, Issue 5, October 2021, 100273].

Reck, M.; (...); John, T.

Correction. 10.1016/j.esmoop.2021.100345. 2021


Current treatment landscape for oligometastatic non-small cell lung cancer

Garde-Noguera, Javier; (...); Counago, Felipe

Article. 10.5306/wjco.v13.i6.485. 2022


Characterization of patients with advanced non-small-cell lung cancer (NSCLC) harboring KRASG12C mutation and their associated direct healthcare costs in Spanish routine clinical practice (SILK study)

Aransay, N. Reguart; (...); Vila, A. Lloansi

Meeting Abstract. 10.1016/j.annonc.2023.09.2442. 2023


Chronological and Biological Age as a Response Factor to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer

Suay, G.; (...); Juan-Vidal, O.

Meeting Abstract. 2024


Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study.

Ahn, Myung-Ju; (...); Sands, Jacob

Article. 10.1200/JCO-24-01544. 2024


Datopotamab Deruxtecan Vs Docetaxel in Patients with Non-Small Cell Lung Cancer: Final Overall Survival from TROPION-Lung01

Sands, J.; (...); Ahn, M-J

Meeting Abstract. 2024


Description of the clinical characteristics and survival in patients with metastatic NSCLC in the Spanish population: An analysis of the thoracic tumours registry (RTT study)

Franco, F; (...); Pulla, MP

Meeting Abstract. 10.1016/j.annonc.2020.08.1694. 2020


Determination of essential biomarkers in lung cancer: A real-world data study in Spain

Calvo de Juan, V.; (...); Provencio Pulla, M.

Meeting Abstract. 10.1016/j.annonc.2022.02.048. 2022


Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics

Provencio, Mariano; (...); Torrente, Maria

Article. 10.1186/s12885-022-09830-8. 2022


Development of a predictive model for early detection of lung cancer: SREAL-eLUNG study

Vidal, O. J. Juan; (...); Martinez, B. Valdivieso

Meeting Abstract. 2023


Development, Implementation and Assessment of Molecular Diagnostics by Next Generation Sequencing in Personalized Treatment of Cancer: Experience of a Public Reference Healthcare Hospital.

Simarro J; (...); Palanca S

Article. 10.3390/cancers11081196. 2019


Durvalumab (D) plus tremelimumab (T) in platinum-refractory/resistant extensive-stage small cell lung cancer (ES-SCLC): Efficacy, safety and ctDNA dynamics from Arm A of the phase 2 BALTIC study

Reinmuth, Niels; (...); Bondarenko, Igor

Meeting Abstract. 2022


Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open -label phase III study

Ferris, RL; (...); Licitra, L

Article. 10.1016/j.annonc.2020.04.001. 2020


ECONOMIC BURDEN OF ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) PATIENTS HARBORING KRASG12C MUTATION IN SPAIN

Fernandez-Barcelo, C.; (...); Sampietro-Colom, L.

Meeting Abstract. 2023


ECONOMIC IMPACT OF THE NSCLC MOLECULAR DIAGNOSIS IN SPAIN: A RETROSPECTIVE ANALYSIS OF HEALTHCARE RESOURCES USE AND ASSOCIATED COSTS FROM THE LUNG-ONE STUDY

de Castro, J; (...); Rojo, F

Meeting Abstract. 2020


Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, in non-small-cell lung cancer (NSCLC) with c-METexon 14 skipping mutations (METex14).

Brandao, Mariana da Rocha Almeida; (...); Felip, Enriqueta

Meeting Abstract. 2024

  • Open Access.

Efficacy RENO Study Results of Oral Vinorelbine or Etoposide with Cisplatin Et Chemo-Radiation in Stage III NSCLC. SLCG 10/02

Isla, D; (...); Provencio, M

Meeting Abstract. 10.1016/j.jtho.2016.11.421. 2017


Endothelin-1-Mediated Drug Resistance in EGFR-Mutant Non-Small Cell Lung Carcinoma

Pulido, I; (...); Shimamura, T

Article. 10.1158/0008-5472.CAN-20-0141. 2020


Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the Thoracic Tumor Registry

Franco, F; (...); Provencio, M

Article. 10.1371/journal.pone.0251761. 2021


Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial

Rosell, R; (...); BELIEF collaborative group

Article. 10.1016/S2213-2600(17)30129-7. 2017


European Society of Medical Oncology (ESMO) guidelines for oncogene-addicted metastatic non-small cell lung cancer (NSCLC): a personalized treatment for each patient.

Suay, Guillermo, Aparisi, Francisco, Juan-Vidal, Oscar

Article. 10.21037/cco-23-100. 2024


Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung Cancer.

Arriola E; (...); Felip E

Article. 10.1007/s40261-024-01379-7. 2024


Extended follow-up of DURVAST trial: A phase II study evaluating durvalumab treatment in HIV-1-infected patients with solid tumours by the Spanish lung cancer group

Cao, MG; (...); Costa, RR

Meeting Abstract. 10.1016/j.annonc.2020.08.1589. 2020


Extensive stage (ES) small-cell lung cancer (SCLC) in Spain: A review of demographic, epidemiological and clinical data from the Thoracic Tumors Registry (TTR study)

Calvo, V; (...); Pulla, MP

Meeting Abstract. 10.1016/j.annonc.2020.08.1555. 2020


FAMetA: a mass isotopologue-based tool for the comprehensive analysis of fatty acid metabolism.

Alcoriza-Balaguer MI; (...); Lahoz A

Article. 10.1093/bib/bbad064. 2023


Family History of Cancer and Lung Cancer: Information from the Thoracic Tumors Registry (TTR Study)

Calvo, V.; (...); Provencio, M.

Meeting Abstract. 2021


Final results of RENO study: Randomized phase II of oral vinorelbine or etoposide with cisplatin & chemo-radiation in stage III NSCLC - SLCG 10/02

Pulla, MP; (...); Casado, MDI

Meeting Abstract. 2018


Final results of RENO study: Randomized phase II of oral vinorelbine or etoposide with cisplatin and chemoradiation in stage III NSCLC. SLCG 10/02.

Provencio-Pulla, Mariano; (...); Isla, Dolores

Meeting Abstract. 10.1200/JCO.2018.36.15_suppl.e20521. 2018


First-line (1L) nivolumab (N) plus ipilimumab (I) plus chemotherapy (C) vs C alone in patients (pts) with metastatic NSCLC (mNSCLC) from CheckMate 9LA: 4-y clinical update and outcomes by tumor histologic subtype (THS)

Carbone, David Paul; (...); Reck, Martin

Meeting Abstract. 2023


First-line (1L) nivolumab (N) plus ipilimumab (I) plus chemotherapy (C) vs C alone in patients (pts) with metastatic NSCLC (mNSCLC) from CheckMate 9LA: 4-y clinical update and outcomes by tumor histologic subtype (THS).

Carbone, David Paul; (...); Reck, Martin

Meeting Abstract. 10.1200/JCO.2023.41.17_suppl.LBA9023. 2023


First-line avelumab in combination with cetuximab and chemotherapy in patients with advanced squamous non-small cell lung cancer (NSCLC)

Andric, Z. G.; (...); Ciardiello, F.

Meeting Abstract. 2021


First-line Nivolumab (N) plus Ipilimumab (I) plus Chemotherapy (C) in Metastatic NSCLC (mNSCLC): CheckMate 9LA 4-Year Clinical Update

Baclin, Firas; (...); Reck, Martin

Meeting Abstract. 2024


First-line nivolumab (NIVO) plus ipilimumab (IPI) plus two cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non-small cell lung cancer (NSCLC): Two-year update from CheckMate 9LA.

Reck, Martin; (...); John, Tom

Meeting Abstract. 10.1200/JCO.2021.39.15_suppl.9000. 2021


First-line nivolumab (NIVO) plus ipilimumab (IPI)+2 cycles chemotherapy (chemo) vs 4 cycles chemo in advanced non-small cell lung cancer (aNSCLC): Association of blood and tissue tumor mutational burden (TMB) with efficacy in CheckMate 9LA

Paz-Ares, L.; (...); Carbone, D. P.

Meeting Abstract. 2021


First-line nivolumab (NIVO) plus ipilimumab (IPI)+2 cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non-small cell lung cancer (NSCLC): 2-year update from CheckMate 9LA

Reinmuth, N.; (...); John, T.

Meeting Abstract. 2021


First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.

Paz-Ares, Luis; (...); Reck, Martin

Article. 10.1016/S1470-2045(20)30641-0. 2021


First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817.

Ready, Neal E.; (...); Paz-Ares, Luis

Article. 10.1136/jitc-2022-006127. 2023


First-line Nivolumab plus Ipilimumab plus Chemo in Patients With Advanced NSCLC and Brain Metastases: Results From CheckMate 9LA

Carbone, D.; (...); Lu, S.

Meeting Abstract. 2021


First-Line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic NSCLC in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations

Paz-Ares, Luis G.; (...); Carbone, David P.

Article. 10.1016/j.jtho.2022.10.014. 2023


First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update.

Reck M; (...); John T

Article. 10.1016/j.esmoop.2021.100273. 2021


First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes.

Reck, Martin; (...); Carbone, David P.

Article. 10.1016/j.ejca.2023.01.015. 2023


Five-year outcomes with first-line (1L) nivolumab plus ipilimumab plus chemotherapy (N plus I plus C) vs C in patients (pts) with metastatic NSCLC (mNSCLC) in CheckMate 9LA.

Reck, Martin; (...); Paz-Ares, Luis G.

Meeting Abstract. https://doi.org/10.1200/JCO.2024.42.16_suppl.8560. 2024


Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial.

Reck M; (...); Paz-Ares LG

Article. 10.1016/j.ejca.2024.114296. 2024


Follicular lymphoma: clinical and mollecular characteristics of histologic transformation

Garcia, MM; (...); Pulla, MP

Meeting Abstract. 2017


Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial.

Carbone DP; (...); Reck M

Article. 10.1136/jitc-2023-008189. 2024


FURTHER: A global study to evaluate furmonertinib in patients with EGFR mutant NSCLC including uncommon EGFR mutations (FURMO-002)

Le, Xiuning; (...); Wang, Jie

Meeting Abstract. https://doi.org/10.1200/JCO.2024.42.16_suppl.TPS8666. 2024

  • Open Access.

FURTHER: A Global, Randomized Study of Firmonertinib at Two Dose Levels in TKI-Naive, Advanced NSCLC with EGFR PACC Mutations

Le, X.; (...); Wang, J.

Meeting Abstract. 2024


GALLANT-1: Galectin-3 (Gal-3) inhibitor GB1211 plus atezolizumab (atezo) in patients with non-small cell lung cancer (NSCLC)-A randomized, double-blind trial.

Ghiringhelli, Francois; (...); Basse, Linda

Meeting Abstract. 2022


Genetic Susceptibility in Head and Neck Squamous Cell Carcinoma in a Spanish Population

Fernandez-Mateos, J; (...); Cruz-Hernandez, JJ

Article. 10.3390/cancers11040493. 2019


Genotypic Characteristics and Resistance Mutations in Advanced ALK plus NSCLC: The ALK-PATHFINDER Study

Lopez Castro, R.; (...); Ponce Aix, S.

Meeting Abstract. 2023


Health-Related Quality of Life (HRQoL) Outcomes with Adagrasib vs Docetaxel in KRASG12C-Mutated Advanced NSCLC in KRYSTAL-12

Felip, E.; (...); Duruisseaux, M.

Meeting Abstract. https://doi.org/10.1016/j.jtho.2024.09.056. 2024


Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments

Gisbert JP; (...); McNicholl AG

Article. 10.1111/apt.13128. 2015


High risk of thrombosis in patients with advanced lung cancer harboring rearrangements in ROS1.

Muñoz-Unceta N; (...); Grupo de trombosis y cáncer SEOM

Article. 10.1016/j.ejca.2020.10.002. 2020


Immune checkpoint inhibitors as first-line treatment for brain metastases in stage IV NSCLC patients without driver mutations

Suay, Guillermo; (...); Lahoz, Agustin

Review. 10.1016/j.canlet.2024.217317. 2024


Immunogenicity of COVID-19 vaccines in lung cancer patients.

Provencio M; (...); Calvo V

Article. 10.1016/j.lungcan.2023.107323. 2023


Immunotherapy, chemotherapy and stereotactic radiotherapy to metastases, followed by definitive surgery or radiotherapy to the primary tumour, in patients with synchronous oligo-metastatic NSCLC: The ETOP CHESS trial

Guckenberger, M; (...); Stahel, RA

Meeting Abstract. 10.1016/j.annonc.2020.08.1731. 2020


Impact of Molecular Testing Using Next-Generation Sequencing in the Clinical Management of Patients with Non-Small Cell Lung Cancer in a Public Healthcare Hospital.

Simarro, Javier; (...); Palanca, Sarai

Article. 10.3390/cancers15061705. 2023


Impact of treatment in long-term survival patients with follicular lymphoma: A Spanish Lymphoma Oncology Group registry

Provencio, M; (...); GOTEL Spanish Lymphoma Oncology Gr

Article. 10.1371/journal.pone.0177204. 2017


Increased Tumor Growth Rate and Mesenchymal Properties of NSCLC-Patient-Derived Xenograft Models during Serial Transplantation

Pardo-Sanchez, JM; (...); Farras, R

Article. 10.3390/cancers13122980. 2021


KRYSTAL-12: Phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation

Mok, Tony S. K.; (...); Barlesi, Fabrice

Meeting Abstract. 10.1200/JCO.2024.42.17_suppl.LBA8509. 2024


Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B Cell Lymphoma. Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker subanalysis.

Palaz N-Carri N, Natalia; (...); de la Cruz-Merino, Luis

Article. 10.1158/1078-0432.CCR-22-0588. 2022


Lenalidomide plus R-GDP (R2-GDP) in relapsed/refractory diffuse large B-cell lymphoma: Final results of the R2-GDP-GOTEL trial.

Merino, LD; (...); Dominguez, AR

Meeting Abstract. 2020


Liposomal Irinotecan in Adults with Small Cell Lung Cancer who Progressed on Platinum-Based Therapy: Subgroup Analyses by Platinum Sensitivity

Spigel, DR; (...); Bunn, P

Meeting Abstract. 2021


Long-term follow-up of a prospective phase 2 clinical trial of extended treatment with rituximab in patients with B cell post-transplant lymphoproliferative disease and validation in real world patients.

González-Barca E; (...); de Sevilla AF

Article. 10.1007/s00277-020-04056-9. 2020


Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy

De Castro, J; (...); Isla, D

Article. 10.1007/s12094-016-1527-8. 2017


Lung Cancer Symptoms at Diagnosis: Data from the Thoracic Tumors Registry (TTR Study).

Calvo, V; (...); Provencio, M

Meeting Abstract. 2021


Lung cancer symptoms at diagnosis: results of a nationwide registry study.

Ruano-Raviña A; (...); Cerezo S

Article. 10.1136/esmoopen-2020-001021. 2020


LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology

Garrido, P; (...); Felip, E

Article. 10.1002/cam4.4135. 2021


Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group

Remon, J; (...); Reguart, N

Article. 10.1016/j.lungcan.2020.06.034. 2020


Multicenter Study of the Seroprevalence of Antibodies against Covid-19 in Patients with Lymphoma: An Analysis of the Oncological Group for the Treatment and Study of Lymphomas (Gotel)

Franco, F; (...); Provencio, M

Article. 10.3390/curroncol28020118. 2021


Mutational profile of primary breast diffuse large B-cell lymphoma

Franco, F; (...); Sanchez-Beato, M

Article. 10.18632/oncotarget.21986. 2017


nab -Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+).

Morgensztern D; (...); Ong TJ

Article. 10.3389/fonc.2020.569715. 2021


Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin Induction Followed by Nanoparticle Albumin-bound Paclitaxel Maintenance in Squamous Non-Small-cell Lung Cancer (ABOUND.sqm): A Phase III Randomized Clinical Trial.

Spigel DR; (...); ABOUND.sqm Investigators

Article. 10.1016/j.cllc.2020.09.007. 2021


Neumorraquis y neumomediastino espontaneo, rara complicacion asmatica.

Fernandez Garcia C; (...); Gomez J

Article. 10.1016/j.anpedi.2014.11.008. 2015


NIVIPI-BRAIN, A Phase II Study of Nivolumab plus Ipilimumab Combined with Chemotherapy for Patients with NSCLC and Synchronous Brain Metastases

Nadal, E.; (...); Bruna, J.

Meeting Abstract. 2022


Nivolumab (NIVO) plus ipilimumab (IPI)+2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA

Reck, M; (...); Paz-Ares, LG

Meeting Abstract. 2020


Nivolumab (NIVO) plus ipilimumab (IPI)+2 Cycles of Platinum-Doublet Chemotherapy (Chemo) vs. 4 Cycles Chemo as First-Line (1L) Treatment) for Stage IV/Recurrent Non-Small Cell Lung Cancer (NSCLC): CheckMate 9LA

Reck, M; (...); Paz-Ares, LG

Meeting Abstract. 2021


Novel Combinations of Immunotherapies or DNA Damage Repair Inhibitors in Platinum-Refractory Extensive-Stage Small-Cell Lung Cancer: The Phase II BALTIC Study.

Reinmuth, Niels; (...); Bondarenko, Igor

Article. 10.1158/1078-0432.CCR-24-0013. 2024


Opioid-Induced Constipation in Oncological Patients: New Strategies of Management.

Mesía R; (...); Pujol E

Article. 10.1007/s11864-019-0686-6. 2019


Oral vinorelbine versus etoposide with cisplatin and chemo-radiation as treatment in patients with stage III non-small cell lung cancer: A randomized phase II (RENO study).

Isla D; (...); Provencio M

Article. 10.1016/j.lungcan.2018.11.041. 2019


Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group.

Provencio M; (...); Calvo V

Article. 10.1186/s12885-021-07922-5. 2021


OsimertinibTreatment in Non-Small Cell Lung Cancer (NSCLC) EGFR-T790M+. Activity in Patients with CNS Metastases. OSIREX

Terrasa, J; (...); Provencio, M

Meeting Abstract. 2021


Pain Standards for Accredited Healthcare Organizations (ACDON Project): A Mixed Methods Study.

Perez, Concepcion; (...); Mira, Jose J.

Article. 10.3390/jpm11020102. 2021


PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma Patients.

Remon J; (...); Besse B

Article. 10.1016/j.cllc.2021.07.008. 2021


Pembrolizumab re-challenge in patients with relapsed non-small cell lung cancer (NSCLC): A preliminary report of the REPLAY phase II trial - cohort I

Ponce Aix, S.; (...); Paz-Ares, L.

Meeting Abstract. 10.1016/j.annonc.2021.10.179. 2021


Peripheral T-cell lymphoma with a T follicular-helper phenotype: A different entity? Results of the Spanish Real-T study.

Martin Garcia-Sancho, Alejandro; (...); Cordoba, Raul

Article. 10.1111/bjh.18941. 2023


Phase II study of panitumumab and paclitaxel as first-line treatment in recurrent or metastatic head and neck cancer. TTCC-2009-03/VECTITAX study

Morillo, ED; (...); Spanish Head Neck Canc Cooperative

Article. 10.1016/j.oraloncology.2016.09.009. 2016


Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05).

Nadal E; (...); Bruna J

Article. 10.1200/JCO.22.02561. 2023


Plain language summary: tarlatamab for patients with previously treated small cell lung cancer.

Ahn, Myung-Ju; (...); Paz-Ares, Luis

Article. 10.1080/14796694.2024.2402152. 2024


Post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation.

Romero S; (...); Sanz J

Article. 10.1080/10428194.2018.1474462. 2019


Preliminary results from PROPEL: A phase I/II study of bempegaldesleukin (BEMPEG: NKTR-214) plus pembrolizumab (PEMBRO) with or without chemotherapy in patients with metastatic NSCLC

Felip, E.; (...); Ganti, A.

Meeting Abstract. 10.1016/j.annonc.2021.10.159. 2021


Pretreatment T790M mutation detection by ultrasensitive PCR assay as predictor of efficacy in non-small lung cancer (NSCLC) patients treated with 1st or 2nd generation EGFR tyrosine kinase inhibitors (TKIs)

Vidal, OJJ; (...); Palanca, S

Meeting Abstract. 2019


Primary Breast Lymphoma: Analysis of 55 Cases of the Spanish Lymphoma Oncology Group

Franco Pérez F; (...); Provencio M

Article. 10.1016/j.clml.2016.09.004. 2017


Profile of Comorbidities and Cancer History in Patients with mNSCLC in the Spanish Population (Thoracic Tumors Registry).

Franco, F; (...); Provencio, M

Meeting Abstract. 2021


Prognostic factors in oligometastatic non-small-cell lung cancer (OM-NSCLC)

Juan, O; (...); Codina, JG

Meeting Abstract. 10.1016/S1556-0864(18)30411-8. 2018


Prognostic factors in oligometastatic non-small-cell lung cancer (OM-NSCLC) patients treated with ablative therapy.

Antonio Mendez, Juan; (...); Juan Vidal, Oscar

Meeting Abstract. 10.1200/JCO.2018.36.15_suppl.e21089. 2018


Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data

Gutierrez, L; (...); Provencio, M

Article. 10.1186/s12885-021-08713-8. 2021


Prognostic Nutritional Index as an independent prognostic factor in locoregionally advanced squamous cell head and neck cancer.

Bruixola, G; (...); Cervantes, A

Article. 10.1136/esmoopen-2018-000425. 2018


Prognostic Value of Event-Free Survival at 12 and 24 Months and Long-Term Mortality for Non-Hodgkin Follicular Lymphoma Patients: A Study Report From the Spanish Lymphoma Oncology Group

Provencio, M; (...); Spanish Lymphoma Oncology Grp

Article. 10.1002/cncr.30795. 2017


PROPEL: A Phase 1/2 Trial of Bempegaldesleukin (NKTR-214) Plus Pembrolizumab in Lung Cancer and other Advanced Solid Tumors

Spigel, DR; (...); Reck, M

Meeting Abstract. 2021


Proposal and validation of a method to classify genetic subtypes of diffuse large B cell lymphoma.

Pedrosa, Lucia; (...); Sanchez-Beato, Margarita

Article. 10.1038/s41598-020-80376-0. 2021


Prospective Exploratory Analysis of Angiogenic Biomarkers in Peripheral Blood in Advanced NSCLC Patients Treated With Bevacizumab Plus Chemotherapy: The ANGIOMET Study

Jantus-Lewintre, E; (...); Grp Espanol Canc Pulmon GECP

Article. 10.3389/fonc.2021.695038. 2021


Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer.

Edelman, Martin J.; (...); DISTINCT Study Investigators

Article. 10.1016/j.lungcan.2022.03.003. 2022


Real-world outcomes of first-line pembrolizumab (Pem) for metastatic non-small cell lung cancer (mNSCLC) with >= 50% expression of programmed cell death-ligand 1 (PD-L1): A multicentre retrospective study

Perea, J.; (...); Gaudens, P. Capdevila

Meeting Abstract. 2023


Recommendations of GeSIDA/PETHEMA on the Diagnosis and Treatment of Lymphomas in Patients Infected by the Human Immunodeficiency Virus

Miralles, P; (...); Santasusana, JMR

Editorial Material. 10.1016/j.medcli.2017.11.037. 2018


RESILIENT part 1: A phase 2 dose-exploration and dose-expansion study of second-line liposomal irinotecan in adults with small cell lung cancer.

Paz-Ares, Luis; (...); Bunn, Paul A.

Article. 10.1002/cncr.34123. 2022


RESILIENT part 1: Pharmacokinetics of second-line (2L) liposomal irinotecan in patients with small cell lung cancer (SCLC)

Ponce, S; (...); Bunn, PA

Meeting Abstract. 10.1016/j.annonc.2020.08.1554. 2020


RESILIENT Part 1: Safety and Efficacy of Second-Line Liposomal Irinotecan in Patients with Small Cell Lung Cancer

Paz-Ares, L; (...); Bunn, P

Meeting Abstract. 2021


RESILIENT Part 2: A phase 3 Study of Liposomal Irinotecan in Patients with Small-Cell Lung Cancer in the Second-Line Setting

Paz-Ares, L; (...); Bunn, P

Meeting Abstract. 2021


RET Fusion Testing in Advanced Non-Small Cell Lung Carcinoma Patients: the RETING Study

Conde, E.; (...); Lopez-Rios, F.

Meeting Abstract. 2021


RET Fusion Testing in Patients With NSCLC: The RETING Study.

Conde, Esther; (...); Lopez-Rios, Fernando

Article. 10.1016/j.jtocrr.2024.100653. 2024


RET Fusion Testing with FISH and Real-Time PCR: a Comparison with RNA-Based Next-Generation Sequencing in RET Positive NSCLC

Hernandez, S.; (...); Conde, E.

Meeting Abstract. 2022


Sacituzumab govitecan (SG) vs docetaxel (doc) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) previously treated with platinum (PT)-based chemotherapy (chemo) and PD(L)-1inhibitors (IO): Primary results from the phase 3 EVOKE-01 study.

Paz-Ares, Luis G.; (...); Garassino, Marina Chiara

Meeting Abstract. 10.1200/JCO.2024.42.17_suppl.LBA8500. 2024


Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study.

Paz-Ares, Luis G.; (...); Garassino, Marina Chiara

Article. 10.1200/JCO.24.00733. 2024


Sacituzumab Govitecan vs Docetaxel in Patients with mNSCLC Non-responsive to Last Anti-PD-(L)1containing Regimen: EVOKE-01

Garassino, M. C.; (...); Paz-Ares, L. G.

Meeting Abstract. 2024

  • Open Access.

Safety and efficacy of nivolumab (nivo) in platinum-refractory recurrent/metastastic head and neck squamous cell (PR R/M HNSCC) patients (pts): Real-life experience

Bruixola, G; (...); Borgonon, MP

Meeting Abstract. 2018


Second-Line Nivolumab in Relapsed Small-Cell Lung Cancer: CheckMate 331.

Spigel DR; (...); Reck M

Article. 10.1016/j.annonc.2021.01.071. 2021


Second-line treatment in advanced non-squamous (NS) non-small cell lung cancer (NSCLC) patients in Spain, analyzed in the Thoracic Tumor Registry (RTT)

Carcereny Costa, E.; (...); Provencio Pulla, M.

Meeting Abstract. 10.1016/j.annonc.2022.02.062. 2022


SEOM clinical guidelines for the treatment of follicular non-Hodgkin's lymphoma

Provencio Pulla M; (...); Rueda Domínguez A

Article. 10.1007/s12094-015-1437-1. 2015


SEOM clinical guidelines for the treatment of Hodgkin's lymphoma

Rueda Domínguez A; (...); Provencio Pulla M

Article. 10.1007/s12094-015-1429-1. 2015


SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022).

Garcia-Campelo, Rosario; (...); Domine, Manuel

Article. 10.1007/s12094-023-03216-3. 2023


SEOM-GOTEL clinical guidelines on diffuse large B cell lymphoma (2022).

Guma, Josep; (...); Provencio, Mariano

Article. 10.1007/s12094-023-03206-5. 2023


Sequential chemotherapy regimen of induction with panitumumab and paclitaxel followed by radiotherapy and panitumumab in patients with locally advanced head and neck cancer unfit for platinum derivatives. The phase II, PANTERA/TTCC-2010-06 study.

Martínez-Trufero J; (...); Mesía Nin R

Article. 10.1007/s12094-021-02567-z. 2021


Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients (p): SOLID study.

Provencio, Mariano; (...); Cobo, Manuel

Meeting Abstract. 10.1200/JCO.2021.39.15_suppl.8531. 2021


Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients: the SOLID study.

Provencio, Mariano; (...); Cobo, Manuel

Article. 10.21037/tlcr-21-504. 2022


Sex differences in the diagnosis, treatment and prognosis of cancer: the rationale for an individualised approach.

Vera, Ruth; (...); del Alba, Aranzazu Gonzalez

Article. 10.1007/s12094-023-03112-w. 2023


Sex Differences in the Efficacy of Immune Checkpoint Inhibitors in Neoadjuvant Therapy of Non-Small Cell Lung Cancer: A Meta-Analysis

Suay, Guillermo; (...); Juan-Vidal, Oscar

Review. 10.3390/cancers15184433. 2023


Small cell lung cancer (SCLC) extensive stage (ES) in Spain: Efficacy of treatments, data from the thoracic tumours registry (TTR study)

Carcereny Costa, E.; (...); Provencio Pulla, M.

Meeting Abstract. 10.1016/j.annonc.2020.08.1547. 2020


Spanish cardiac catheterization and coronary intervention registry. 32nd official report of the Interventional Cardiology Association of the Spanish Society of Cardiology (1990-2022).

Jurado-Román A; (...); García de la Borbolla Fernández R

Article. 10.1016/j.rec.2023.07.012. 2023


Spatially Preserved Multi-Region Transcriptomic Subtyping and Biomarkers of Chemoimmunotherapy Outcome in Extensive-Stage Small Cell Lung Cancer.

Peressini M; (...); Zugazagoitia J

Article. 10.1158/1078-0432.CCR-24-0104. 2024


Standardized mortality ratios and event-free survival as new prediction tools of early increase in mortality in follicular lymphoma

Franco, F; (...); Pulla, MP

Meeting Abstract. 2017


Stereotactic body radiation therapy: A good dance partner of oligometastatic non-small cell lung cancer to the sound of SINDAS study.

Mielgo-Rubio X; (...); Couñago F

Editorial Material. 10.5306/wjco.v11.i12.983. 2020


Survival in young adults diagnosed with follicular lymphoma

Calvo, V; (...); Rueda, A

Letter. 10.1093/annonc/mdv627. 2016


Survival outcomes in ALK-positive NSCLC patients (p) treated 1st line brigatinib and impact of the ALK fusion variant

Provencio-Pulla, Mariano; (...); Romero, Atocha

Meeting Abstract. 2023


Survival, quality of life (QoL) and geriatric outcomes of elderly patients (pt) with advanced non-small cell lung cancer (NSCLC), treated with pembrolizumab (P) in the first-line setting

Blanco, R; (...); Vidal, OJJ

Meeting Abstract. 10.1016/j.annonc.2020.08.1631. 2020


Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer.

Ahn MJ; (...); Paz-Ares L

Article. 10.1056/NEJMoa2307980. 2023


Technical Validation and Clinical Implications of Ultrasensitive PCR Approaches for EGFR-Thr790Met Mutation Detection in Pretreatment FFPE Samples and in Liquid Biopsies from Non-Small Cell Lung Cancer Patients

Simarro, Javier; (...); Palanca, Sarai

Article. 10.3390/ijms23158526. 2022


The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy.

Gomez Rueda, Ana; (...); Garrido, Pilar

Article. 10.1007/s12094-024-03404-9. 2024


Thoracic Tumors Registry (RTT): Analysis of Clinical Features and Survival in Patients with mNSCLC in Spain.

Franco, F; (...); Provencio, M

Meeting Abstract. 2021


Transcriptomic analysis of pre-treatment tissue samples to predict clinical benefit to durvalumab in HIV-infected cancer patients

Wilhelmina Bracht, Jillian; (...); Rosell, Rafael

Meeting Abstract. 10.1158/1538-7445.AM2020-929. 2020


Transformed follicular lymphoma in the rituximab era: A report from the Spanish Lymphoma Oncology Group

Mendez, M; (...); Provencio, M

Article. 10.1002/hon.2601. 2019


Translation of a tissue epigenetic signature to circulating free DNA suggests BCAT1 as a potential noninvasive diagnostic biomarker for lung cancer

Palanca-Ballester, Cora; (...); Sandoval, Juan

Article. 10.1186/s13148-022-01334-3. 2022


Treatment strategy optimization for patients with non-small-cell lung cancer harboring EGFR mutation: a Delphi consensus.

Isla D; (...); Juan-Vidal O

Article. 10.1007/s12094-020-02518-0. 2021


Unraveling transformation of follicular lymphoma to diffuse large B-cell lymphoma

Gonzalez-Rincon, J; (...); Sanchez-Beato, M

Article. 10.1371/journal.pone.0212813. 2019


Updated analysis from the ATEZO-BRAIN trial: Atezolizumab plus carboplatin and pemetrexed in patients with advanced nonsquamous non-small cell lung cancer with untreated brain metastases.

Nadal, Ernest; (...); Bruna, Jordi

Meeting Abstract. 2022


Utility of Next-Generation Sequencing in the Reconstruction of Clonal Architecture in a Patient with an EGFR Mutated Advanced Non-Small Cell Lung Cancer: A Case Report.

Simarro J; (...); Palanca S

Article. 10.3390/diagnostics12051266. 2022


Campos de estudio

Compartir